Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation

Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation

US Patent 10047103 · Granted Aug 14, 2018

Estimated economic value: $520,335,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

1H-benzo[D]imidazole derivatives as TLR9 inhibitors for the treatment of fibrosi2025
Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative dise2025
Inhibitors of APOL1 and methods of using same2025
Substituted carbazole compounds2025
Modulators of alpha-1 antitrypsin2025
Substituted indole and indazole compounds2024
Apelin receptor agonists and methods of use2024
Inhibitors of protein tyrosine phosphatase, compositions, and methods of use2024
Methods of treating kidney failure, and/or improving or stablizing renal functio2024
Treatment of fibrosis, cardiovascular disease and heart failure with modified re2024
Imidazothiadiazole and imidazopyrazine derivatives as protease activated recepto2024
Imidazothiadiazole and imidazopyrazine derivatives as protease activated recepto2024